Evidence map›Paper›PMID 30205047›Full record

ArticleCancer cell2018

MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.

Paola Brescia, Christof Schneider, Antony B Holmes, Qiong Shen, Shafinaz Hussein, Laura Pasqualucci, Katia Basso, Riccardo Dalla-Favera

Abstract read
In one paragraph

Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Audit of B-cell cancer genes.Blood advances · 2025
    Review
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paola BresciaInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Christof SchneiderInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Antony B HolmesInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Qiong ShenInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA.
Shafinaz HusseinDepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Laura PasqualucciInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA.
Katia BassoInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. Electronic address: kb451@cumc.columbia.edu.
Riccardo Dalla-FaveraInstitute for Cancer Genetics, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Microbiology and Immunology, Columbia University, New York, NY 10032, USA; Department of Genetics and Development, Columbia University, New York, NY 10032, USA; The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA. Electronic address: rd10@cumc.columbia.edu.

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI JOSEPH G JURCIC · 1985 to 2026
$115.3M
From pathogenesis to new therapeutic targets in Diffuse Large B cell LymphomaR35CA210105 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Riccardo Dalla-Favera · 2016 to 2026
$10.0M
Role of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaR01CA172492 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PASQUALUCCI, LAURA · 2013 to 2022
$3.6M
NCI NIH HHS P30 CA013696NCI NIH HHS R01 CA172492NCI NIH HHS R35 CA210105
6 · The paper itself

Abstract

The gene encoding the MEF2B transcription factor is mutated in germinal center (GC)-derived B cell lymphomas, but its role in GC development and lymphomagenesis is unknown. We demonstrate that Mef2b deletion reduces GC formation in mice and identify MEF2B transcriptional targets in GC, with roles in cell proliferation, apoptosis, GC confinement, and differentiation. The most common lymphoma-associated MEF2B mutant (MEF2B

Indexed as

AnimalsApoptosisB-LymphocytesCarcinogenesisCell DifferentiationCell ProliferationDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticGerminal CenterHumansLymphoma, B-CellMaleMEF2 Transcription FactorsMiceMice, Inbred C57BLMEF2B protein, humanMef2b protein, mouseMEF2 Transcription FactorsB cellgerminal centerlymphomaMEF2Bmouse model

Identifiers

PMID30205047
PMCPMC6223119

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.